<DOC>
	<DOCNO>NCT00151736</DOCNO>
	<brief_summary>This Phase 2 , multi-center , open label , randomize clinical study evaluate safety efficiency SDX-101 combination chlorambucil ( CLB ) chlorambucil alone Chronic Lymphocytic Leukaemia ( CLL ) patient . The study treatment period approximately 24-26 week follow-up period approximately 8 week . Following end treatment , patient confirm complete response , partial response stable disease follow 2 year assess time disease progression . Approximately 80 patient documented diagnosis B-cell CLL standard clinical immunophenotyping criterion enrol SDX-101-03 study . This study conduct follow European country : France , Germany , Poland , Sweden United Kingdom .</brief_summary>
	<brief_title>Safety Efficacy SDX-101 ( R-Etodolac ) Combination With Chlorambucil , That Chlorambucil Alone , Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Etodolac</mesh_term>
	<criteria>1 . Diagnosis Bcell CLL standard clinical immunophenotypic criterion specify NCI work group revise guideline diagnosis treatment CLL ( 32 ) . 2 . Binet stag AC evidence active disease require treatment presence one following time study entry : Disease relate B symptom ( Fever &gt; 38C [ 100.5F ] ≥ 2 week without evidence infection , night sweat without evidence infection , weight loss &gt; 10 % within previous 6 mo. ) . Evidence progressive marrow failure manifest : A decrease hemoglobin &lt; 10g/dL , A decrease platelet count &lt; 100 x 10 ( 9 ) /L within previous 6 month , A decrease absolute neutrophil count ( ANC ) &lt; 1.0 x 10 ( 9 ) /L within 6 month Progressive lymphocytosis increase &gt; 50 % 2 month period , anticipate double time &lt; 6 month . Massive node cluster ( i.e. , &gt; 10 cm long diameter ) progressive lymphadenopathy . Progressive splenomegaly &gt; 2cm left costal margin organomegaly progressive increase 2 consecutive clinical visit ≥ 2 week apart . 3 . No prior chemotherapy CLL . 4 . Age ≥ 18 signing inform consent . 5 . World Health Organization ( WHO ) performance status ≤ 02 ( Appendix B ) . 6 . Platelet count &gt; 50,000/μL , hemoglobin &gt; 8.0 g/dl absolute neutrophil count &gt; 1000/μL . 7 . Renal function ≤ 1.5 x upper limit normal ( blood urea nitrogen [ BUN ] , serum creatinine ) 8 . Liver function ≤ 1.5 time upper limit normal ( total bilirubin , SGOT ( AST ) SGPT ( ALT ) value ) . 9 . Female patient childbearing potential must negative pregnancy test ( serum urine Betahuman chorionic gonadotropin , BetaHCG ) ; men woman reproductive potential must employ effective contraceptive method study therapy , 2 month follow completion treatment . 10 . Signed EC/IRBapproved informed consent patient prior study related procedure . 1 . Active autoimmune manifestation CLL ongoing hemolytic anemia ITP 2 . History second malignancy exception cervical cancer , resect basal cell carcinoma malignancy evidence recurrence 5 year since diagnosis . 3 . Chronic viral infection : positive hepatitis B hepatitis C serology , know positive human immunodeficiency virus ( HIV ) human Tleukemia/lymphoma virus ( HTLV ) . 4 . Transformation aggressive Bcell malignancy Richter 's transformation , prolymphocytic leukemia ( PLL ) large Bcell lymphoma . 5 . Clinical evidence CNS involvement CLL . 6 . Serious infection , medical condition , psychiatric condition , opinion investigator , might interfere achievement study objective . 7 . Treatment investigational agent within 4 week study entry . 8 . The use steroid , nonsteroidal antiinflammatory drug , regardless indication ( exclude prophylactic use aspirin prevention acute myocardial infarction stroke ) 9 . Pregnancy currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
</DOC>